Your Health, We Care
Indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have received prior fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, anti-vascular endothelial growth factor (VEGF) therapy and, if RAS is wild-type, anti-epidermal growth factor receptor (EGFR) therapy.
It is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
Indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
from FDA，2020.02
